Avantor to relocate to new and expanded Bridgewater Innovation Center

Avantor, a global provider of mission-critical products and services to customers in the life sciences, education and government, and advanced technologies sectors, on Monday said it will relocate to a new facility plus double the size of its lab and pilot space at its Bridgewater Innovation Center.

The Bridgewater Innovation Center opened in 2017 and serves as a technology-driven research and collaboration environment where Avantor works with customers to develop and enhance their offerings.

About Avantor

Avantor is a chemicals and materials company headquartered in Radnor, Pennsylvania. The Fortune 500 company is a leading global provider of mission-critical products and services to customers in the biopharma, health care, education and government, and advanced technologies and applied materials industries.

Avantor says the expanded Innovation Center will open in August 2024 and will serve as its collaborative hub for supporting customers’ bioprocessing and the growing demands for gene therapy and mRNA workflows, facilitate pipeline project execution and enable quicker production scale-up.

“We are committed to supporting our customers’ requirements and growth, and this expansion allows us to take an even more collaborative approach to deliver customized solutions that move science forward,” Nandkumar Deorkar, senior vice president of research & development and innovation, said. “By adding capacity, talent and capability to our Innovation Center, Avantor is in a stronger position to support the growing demands for gene therapy and mRNA workflows, facilitate pipeline project execution and enable quicker production scale-up. These enhancements will pave the way for the innovations of tomorrow.”

Labs in the new Bridgewater Innovation Center will include upstream and downstream process development, chemistry and material science, analytical and bioanalytical, viral vector workflows and electronic materials.

Larger and more flexible pilot labs with additional capacity and capability to produce novel excipients, resins and biopharma reagents will enable quicker production scale-up for customers. Additional pilot areas for upstream and downstream production will highlight Avantor’s chemical manufacturing and single-use expertise.